A Study on the Peripheral Blood in Patients With Acute Coronary Syndrome
NCT ID: NCT06955143
Last Updated: 2025-07-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
310 participants
OBSERVATIONAL
2025-03-11
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The growth factors that have significant changes in the peripheral blood of the ACS population, especially fibroblast growth factors? Inflammatory factors and chemokines related to the onset of ACS? The metabolites and proteins that are significantly altered in the peripheral blood after the onset of ACS? Researchers will compare ACS population to CCS (Chronic Coronary Syndrome) population, and control group (patients without coronary artery stenosis, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy).The peripheral venous blood from the participants will be collected within 24 hours after their admission to the hospital.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Cohort of Patients Undergoing Percutaneous Coronary Intervention
NCT05719545
A Multi-Omics Study of Vasospastic Angina
NCT05282511
Correlation of Biomarkers With the Presence and Severity of Coronary Artery Disease
NCT05015270
Potential Diagnostic and Prognostic Value of microRNAs for the Patients of Acute Coronary Syndrome
NCT02755207
Registry of Bleeding Risk in Real World Chinese Acute Coronary Syndrome Patients-II
NCT03402711
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ACS
those with a condition of Acute Coronary Syndrome
No interventions assigned to this group
Control
patients without coronary artery disease, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy
No interventions assigned to this group
CCS
those with a condition of Chronic Coronary Syndrome
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* cTn\>99th ULN or CK-MB\>99th ULN
* ST-segment elevation with a convex upward morphology
* in conjunction with one or more of the following conditions: persistent ischemic chest pain; echocardiographic evidence of abnormal segmental ventricular wall motion; or abnormal coronary angiography findings.
NSTEMI
* cTn\>99th ULN or CK-MB\>99th ULN
* accompanied by one or more of the following situations: persistent ischemic chest pain; new ST-segment depression or low and inverted T waves; echocardiography showing segmental ventricular wall motion abnormalities; abnormal coronary angiography.
UA
* cTn normal
* ischemic chest pain with an electrocardiogram showing transient ST-segment depression or flattened and inverted T waves
* evidence of coronary artery stenosis (e.g., CTA demonstrating ≥ 50% stenosis) For CCS group
* Clinical Diagnosis Consistent with CCS Categories, meet any one of the following clinical scenarios: Stable Angina Pectoris, Ischemic Cardiomyopathy, Post-ACS Stable Phase, Long-Term CAD Management, Vasospastic or Microvascular Disease, Asymptomatic CAD
* Laboratory and Imaging Confirmation: Resting ECG without ST-segment elevation or dynamic changes (excluding ACS), cTn normal or stable (no acute myocardial injury), ≥50% luminal stenosis in ≥1 epicardial coronary artery For control group
* Patients without coronary artery stenosis, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy
Exclusion Criteria
* Patients with malignant neoplasms
* Severe hepatic/renal dysfunction
* Severe hematological disorders
* Autoimmune diseases
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Central Hospital of Lishui City
OTHER
Second Affiliated Hospital of Wenzhou Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lishui Central Hospital
Lishui, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SAHoWMU-CR2025-06-218
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.